Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
November 6, 2024 4:47 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $6.61, $1.11 better than the analyst estimate of $5.50. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $19.50-$20.60, versus the consensus of... More
